



Gallbladder and Bile Ducts



Predominantly Unconjugated Hyperbilirubinemia

Predominantly Unconjugated Hyperbilirubinemia

Excess production of bilirubin

- Hemolytic anemias

- Resorption of blood from internal hemorrhage (e.g., alimentary tract bleeding, hematomas)

- Ineffective erythropoiesis syndromes (e.g., pernicious anemia, thalassemia)

Reduced hepatic uptake

- Drug interference with membrane carrier systems

- Some cases of Gilbert syndrome

Impaired bilirubin conjugation

- Physiologic jaundice of the newborn (decreased UGT1A1 activity, decreased excretion)

- Breast milk jaundice (?increased deconjugation by β -glucuronidases)

- Genetic deficiency of bilirubin UGT1A1 activity (Crigler-Najjar syndromes types I and II)

- Gilbert syndrome (decreased expression of UGT1A1)

- Diffuse hepatocellular disease (e.g., viral or drug-induced hepatitis, cirrhosis)

Predominantly Conjugated Hyperbilirubinemia

Predominantly Conjugated Hyperbilirubinemia

Decreased hepatic excretion of bilirubin glucuronides

Deficiency in canalicular membrane transporters (Dubin-Johnson syndrome, Rotor syndrome)

Drug-induced canalicular membrane dysfunction (e.g., oral contraceptives, cyclosporine)

Hepatocellular damage or toxicity (e.g., viral or drug-induced hepatitis, total parenteral nutrition, systemic infection)

Decreased intrahepatic bile flow

Impaired bile flow through bile canaliculi (e.g., drug-induced microfilament dysfunction)

Inflammatory destruction of intrahepatic bile ducts (e.g., primary biliary cirrhosis, primary sclerosing cholangitis, graft-versus-host disease, liver transplantation)

Extrahepatic biliary obstruction

Gallstone obstruction of biliary tree

Carcinomas of head of pancreas, extrahepatic bile ducts, ampulla of Vater

Extrahepatic biliary atresia

Biliary strictures and choledochal cysts

Primary sclerosing cholangitis (extrahepatic)

Liver fluke infestation

CLASSIFICATION – CBD Stones

- **By the point of origin**
 1. Primary CBD Stones
 2. Secondary CBD Stones
- **By the time of discovery relative to cholecystectomy**
 1. Retained
 2. Recurrent

CBD Stone on USG




CBD Stone on EUS

Choledocholithiasis





Clinical presentation				
Clinical diagnosis	Choledocholithiasis	Cholecystitis Pancreatitis Resolving choledocholithiasis	Cholecystitis Pancreatitis Resolving choledocholithiasis	Biliary colic
Ultrasound	CBD \geq 5 mm	CBD \geq 5 mm	CBD < 5 mm	CBD < 5 mm
Serum biochemistries	At least 2 of: T Bili \geq 1.5 Alk phos \geq 150 AST \geq 100 ALT \geq 100	At least 2 of: T Bili \geq 1.5 Alk phos \geq 150 AST \geq 100 ALT \geq 100	At least 2 of: T Bili \geq 1.5 Alk phos \geq 150 AST \geq 100 ALT \geq 100	T Bili < 1.5 Alk phos < 150 AST < 100 ALT < 100



Risk of CBD stones 93% 32% 4% 1%

CBD Stone on ERCP





CONCLUSION

- CBD Stones associated in 10 – 15 % pts undergoing cholecystectomy
- Advanced endoscopic & laparoscopic techniques have revolutionised management
- Treatment depends on resources, technical limitations, surgeons expertise
- LCBDE is safe, feasible, single stage management option for CBD stones